Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma
Open Access
- 2 July 2003
- Vol. 98 (2) , 424-430
- https://doi.org/10.1002/cncr.11506
Abstract
BACKGROUND In previous studies, the authors showed that various types of cultured tumor cells treated with exogenous bikunin protein or ovarian carcinoma cells transfected with bikunin cDNA have low invasiveness and diminished metastatic potential. This study was carried out to clarify the relation between the expression of individual bikunin mRNA and tumor progression. METHODS Forty-one newly diagnosed ovarian carcinomas were investigated using a semiquantitative reverse transcriptase-polymerase chain reaction. RESULTS The authors found that 24 patients had tumors that overexpressed bikunin and that gene expression was reduced in the tumors of the remaining 17 individuals. Bikunin mRNA expression was independent of age, surgical stage, tumor size, degree of differentiation, histologic subtype, and serum CA 125 levels. There was a significant correlation between low expression of bikunin mRNA and lymph node status (P = 0.035) or peritoneal status (P = 0.042). Multivariate analysis indicated that bikunin was an independent prognostic marker (P = 0.013; hazard ratio, 2.30; 95 % confidence interval, 1.13–4.19), even after controlling for lymph node metastasis and the degree of peritoneal dissemination. In addition, low expression was a significant predictor for poor prognosis compared with high expression (2-year survival rate; 75.0 % vs. 47.1 %, respectively; P < 0.05). CONCLUSIONS The data suggest that low bikunin mRNA expression by ovarian cacinoma cells may be associated with poor prognosis. It is conceivable that testing for bikunin mRNA may identify patients with ovarian carcinoma who are at high risk for early disease recurrence and a poor prognosis. Cancer 2003;98:424–30. © 2003 American Cancer Society. DOI 10.1002/cncr.11506Keywords
This publication has 29 references indexed in Scilit:
- Cyclooxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian CancerGynecologic Oncology, 2002
- EGFR and cancer prognosisPublished by Elsevier ,2001
- Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling PathwaysPublished by Elsevier ,2001
- Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?Acta Oncologica, 2000
- Immunohistochemical Distribution of Inter-α-trypsin Inhibitor Chains in Normal and Malignant Human Lung TissueJournal of Histochemistry & Cytochemistry, 1999
- Gene Expression of the Two Heavy Chains and One Light Chain Forming the Inter-Alpha-Trypsin-Inhibitor in Human Tissues.Biological & Pharmaceutical Bulletin, 1998
- The role of the HER-2/ oncogene in gynecologic cancersJournal of the Society for Gynecologic Investigation, 1996
- Inhibition of metastasis of lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis modelsInternational Journal of Cancer, 1995
- Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cellsInternational Journal of Cancer, 1994
- Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasionClinical & Experimental Metastasis, 1994